Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
Topriceanu, Constantin-Cristian, Christoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, Mark W Russell, Kenneth Zahka, Alexandre C Pereira, et al. 2025. “Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.”. Circulation. Heart Failure 18 (6): e012393.